Consumer Genetic Testing Market

Overview

The global Consumer Genetic Testing Market was valued at USD 2.8 billion in 2025 and is projected to reach USD 18.7 billion by 2034, growing at a CAGR of 23.5% during the forecast period (2026-2034). The market growth is driven by rising consumer interest in personalized health, wellness, ancestry, and nutrigenomics insights, alongside declining sequencing costs, expanding online retail access, and the growing integration of genetic data with digital health and telemedicine platforms. The market is shifting from single-purpose ancestry and relationship kits toward clinically meaningful, subscription-based health platforms that combine polygenic risk scoring, pharmacogenomics, and continuous report updates. Government initiatives such as India's GenomeIndia initiative, led by the Department of Biotechnology to build a large-scale national genomic reference database, and the continued development of internationally recognized quality standards such as ISO/TS 20738:2026 for DTC genetic data analysis, are supporting standardization, consumer trust, and cross-border regulatory alignment across the consumer genetic testing value chain. By region, North America held the largest share of the market in 2025, supported by high consumer awareness, established players, and broad online distribution. Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by rising disposable incomes, improving healthcare infrastructure, expanding e-commerce penetration, and government-backed genomics and precision medicine programs across China, India, Japan, and South Korea.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Shift Toward Whole Genome Sequencing and Polygenic Risk Scoring Emerging as a Transformational Trend

• Providers are progressively upgrading from single nucleotide polymorphism (SNP) microarray chips to whole genome sequencing to deliver more comprehensive ancestry, health, and trait insights from a single sample.
• Expansion of polygenic risk scoring is enabling companies to move beyond single-gene analysis toward multi-variant modeling across cardiovascular, metabolic, and bone-health conditions, supporting premium subscription pricing tiers.
• Integration of consumer genetic data with wearables, telehealth platforms, and electronic medical records is shifting the category from static one-time reports toward dynamic, continuously updated health insights.
• BGI Group contributed to the development of ISO/TS 20738:2026, the first international standard addressing data analysis consistency and reliability for direct-to-consumer genetic testing.

KEY MARKET DRIVER:

Rising Consumer Demand for Personalized Health and Preventive Wellness is Driving Market Growth

• Consumers are increasingly using genetic tests to understand hereditary disease risk, carrier status, and nutrigenomic profiles as part of proactive, preventive approaches to personal health management.
• Declining costs of genomic sequencing and microarray genotyping continue to make consumer genetic tests more affordable and accessible to a broader mainstream customer base.
• Expansion of online and direct retail distribution channels allows providers to reach consumers without requiring a clinical visit, shortening the purchase-to-result cycle.
• Government initiatives promoting preventive healthcare, personalized medicine, genomic testing, and digital health adoption are improving consumer awareness and access. Public programs supporting early disease detection and individualized health management are encouraging proactive wellness and personalized preventive care.

KEY MARKET OPPORTUNITY

Expansion of Subscription-Based Genomic Health Platforms Creates Significant Market Opportunity

• Providers have an opportunity to convert one-time DNA kit purchasers into recurring subscribers by layering ongoing health, nutrition, and pharmacogenomic report updates on top of existing genomic data.
• Emerging markets across Asia-Pacific, Latin America, and the Middle East remain comparatively underpenetrated, offering room for regional expansion supported by rising disposable incomes and growing genomics awareness.
• Government-backed national genomics programs are expanding reference databases that can improve the accuracy and relevance of ancestry and health-risk interpretation for regional populations.
• 23andMe partnered with HealthEx to connect consenting customers' medical records with their genetic information, reflecting the broader industry move toward integrated, subscription-based consumer genomics platforms.

Consumer Genetic Testing Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Test Type

Predictive testing held the largest market share in 2025, supported by strong consumer interest in understanding disease-risk predisposition, carrier status, and other health-related genetic markers. Predictive tests are widely marketed as tools for proactive health management, and their integration with polygenic risk scoring has expanded their clinical relevance beyond simple wellness reporting.

Nutrigenomics testing is projected to grow at the fastest CAGR during the forecast period, driven by rising consumer focus on personalized nutrition, weight management, and lifestyle optimization. Growing demand for diet plans tailored to individual genetic profiles is expected to support continued adoption of nutrigenomics-focused test kits and subscription reports. Expanding consumer awareness of gene–diet interactions is also encouraging broader adoption of nutrigenomics testing.

Test Type categories include

• Predictive Testing (Dominating Segment)
• Nutrigenomics Testing (Highest CAGR Segment)
• Carrier Testing
• Relationship Testing
• Others

Analysis by Technology

Whole genome sequencing (WGS) held the largest market share in 2025, supported by its ability to provide the most comprehensive view of an individual's genetic makeup, spanning ancestry, inherited traits, and disease-risk insights in a single test. Several leading providers have transitioned their flagship products from SNP-chip genotyping to WGS to strengthen the depth and long-term value of their reports.

Single nucleotide polymorphism (SNP) chip-based testing is projected to grow at the fastest CAGR during the forecast period, supported by its lower cost per test relative to full sequencing, which continues to make it the preferred entry-level technology for price-sensitive consumers in emerging markets. Continued improvements in SNP coverage and interpretation capabilities are expected to strengthen its use across ancestry, wellness, and trait-focused applications.

Technology categories include

• Whole Genome Sequencing (Dominating Segment)
• Single Nucleotide Polymorphism (SNP) Chips (Highest CAGR Segment)
• Targeted Analysis
• Others

Analysis by Distribution Channel

The online platform segment held the largest market share in 2025, as digital storefronts, direct-to-consumer marketing, and e-commerce integration allow companies to reach a broad consumer base with minimal friction between marketing and purchase. Online distribution also supports subscription-based report models and targeted digital marketing campaigns.

The over-the-counter (OTC) segment is projected to grow at the fastest CAGR during the forecast period, supported by increasing retail pharmacy and specialty store placement, which improves consumer trust and provides an accessible, walk-in alternative to online ordering for first-time genetic testing customers. This growth is further supported by expanding product availability across pharmacies, health retailers, and wellness stores, along with increased consumer awareness of at-home genetic testing. Improved in-store guidance and product visibility are also encouraging adoption among first-time users.

Distribution Channel categories include

• Online Platform (Dominating Segment)
• Over-the-Counter (Highest CAGR Segment)

Analysis by Sample Type

Saliva-based sample collection held the largest market share in 2025, supported by its non-invasive nature, ease of at-home self-collection, and compatibility with standard mail-in laboratory workflows used by most leading consumer genetic testing providers. Its simple collection process, low handling requirements, and convenient room-temperature shipping also reduce barriers for consumers, supporting widespread adoption across ancestry, wellness, and health-focused genetic testing applications.

Blood-based sample collection is projected to grow at the fastest CAGR during the forecast period, supported by its use in higher-accuracy clinical-grade health and pharmacogenomic test offerings that require greater sample quality than saliva-based collection can provide. Increasing integration of clinically oriented genetic testing with healthcare providers and telehealth platforms is also expanding its use.

Sample Type categories include

• Saliva (Dominating Segment)
• Blood (Highest CAGR Segment)
• Buccal Swab
• Others

By Region

Consumer Genetic Testing Market Share 2025, (%)

North America

60%

South America

xx%

Europe

18%

Middle East Africa

xx%

Asia Pacific

xx%

North America held the largest market share in 2025, supported by high consumer awareness, well-established providers, and broad online and retail distribution across the United States, Canada, and Mexico. The United States represented the largest country market, driven by the presence of leading consumer genetic testing companies, large proprietary DNA databases, and strong demand for ancestry, relationship, and health-risk testing. Canada also benefits from growing consumer adoption of direct-to-consumer genetic testing and expanding digital health services, while Mexico is supported by rising healthcare access, increasing awareness of personalized health, and expanding availability of genetic testing through private healthcare channels. Regulatory oversight from the U.S. Food and Drug Administration for certain health-risk tests, together with consumer protections under the Genetic Information Nondiscrimination Act, provides a structured operating environment. Continued scrutiny following the 2025 bankruptcy and asset sale of 23andMe to the TTAM Research Institute has intensified consumer and regulatory focus on genetic data privacy, prompting providers to strengthen data governance practices across the region.

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period, driven by improving healthcare infrastructure, rising disposable incomes, expanding e-commerce penetration, and increasing consumer interest in personalized health and wellness. China represented the largest country market, supported by its large consumer base, growing domestic genomics industry, and increasing adoption of genetic testing for health, ancestry, and wellness applications. India is projected to be the fastest-growing country market, supported by rising healthcare digitization, increasing awareness of preventive health, expanding private genetic testing services, and government-backed genomics programs, including the GenomeIndia initiative under the Department of Biotechnology, which is advancing large-scale genome sequencing to build a national genetic reference database. Japan and South Korea maintain strong positions in high-precision sequencing, biotechnology, and technology development, supporting the broader regional ecosystem, while the rest of Asia-Pacific is benefiting from improving healthcare access and expanding distribution of at-home testing products.

Countries and Regions Covered

North America (Dominating Region)

• United States (Largest Country Market)
• Canada
• Mexico

Asia-Pacific (Fastest Growing Region)

• China (Largest Country Market)
• India (Fastest-Growing Country Market)
• Japan
• South Korea
• Rest of Asia-Pacific

Europe

• United Kingdom (Largest Country Market)
• Germany
• France
• Italy
• Rest of Europe

Latin America

• Brazil (Largest Country Market)
• Chile (Fastest-Growing Country Market)
• Rest of Latin America

Middle East & Africa

• United Arab Emirates (Largest Country Market)
• Saudi Arabia (Fastest-Growing Country Market)
• Rest of Middle East & Africa

Market Share

The market is consolidated, with a small number of globally recognized brands, including Ancestry.com LLC, MyHeritage Ltd., Gene by Gene, Ltd. (FamilyTreeDNA), Living DNA Ltd., MapmyGenome India Ltd., Dante Labs S.r.l., GenePlanet d.o.o., tellmeGen S.L., CRI Genetics LLC, African Ancestry, Inc., 24Genetics S.L., Genoplan Korea Inc., Genebase Systems Inc., FitnessGenes Ltd., and Muhdo Health Ltd., holding substantial brand visibility and customer reach, alongside numerous regional and niche providers competing in specialized segments such as nutrigenomics, pharmacogenomics, ancestry testing, and whole genome sequencing. Competitive dynamics center on proprietary database size, scientific validation of health reports, pricing transparency, data-privacy positioning, and integration with telehealth or digital health platforms. Following the 2025 bankruptcy and asset sale of 23andMe, providers across the industry have placed greater strategic emphasis on data governance and privacy commitments. Leading companies are prioritizing whole genome sequencing upgrades, subscription-based health reporting, and partnerships with telehealth and digital health platforms to strengthen long-term customer engagement and differentiate from lower-cost regional competitors.

Key Players

• Ancestry.com LLC (United States)
• MyHeritage Ltd. (Israel)
• Gene by Gene, Ltd. (FamilyTreeDNA) (United States)
• Living DNA Ltd. (United Kingdom)
• MapmyGenome India Ltd. (India)
• Dante Labs S.r.l. (Italy)
• GenePlanet d.o.o. (Slovenia)
• tellmeGen S.L. (Spain)
• CRI Genetics LLC (United States)
• African Ancestry, Inc. (United States)
• 24Genetics S.L. (Spain)
• Genoplan Korea Inc. (South Korea)
• Genebase Systems Inc. (Canada)
• FitnessGenes Ltd. (United Kingdom)
• Muhdo Health Ltd. (United Kingdom)

Recent Market Developments

• February 2025: Prenetics partnered with Humanity Protocol to use CircleDNA’s genetic testing capabilities for blockchain-based decentralized identity verification.
• July 2025: TTAM Research Institute acquired 23andMe through a $305 million bankruptcy sale, transitioning the consumer genetic testing company to a nonprofit model focused on genetic research, data privacy, and health equity.
• September 2025: Ancestry.com LLC (US) introduced its 2025 AncestryDNA origins update, expanding reference population data to deliver more granular ethnicity estimation and geographic ancestry insights for customers.
• October 2025: MyHeritage Ltd. upgraded its consumer DNA testing service to whole genome sequencing using technology from Ultima Genomics, becoming the first major consumer DNA testing company to adopt large-scale WGS across its customer base.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is Consumer Genetic Testing?

2

What is the CAGR of the Consumer Genetic Testing Market?

3

Which test type leads the Consumer Genetic Testing Market?

4

Which technology dominates the Consumer Genetic Testing Market?

5

Which distribution channel has the highest market share?

6

What are the latest trends in the Consumer Genetic Testing Market?

7

Who are the end users of Consumer Genetic Testing?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates